Cancer Immunotherapy Group Publications
Huck SP, Tang SC, Andrew KA, Yang J, Harper JL, Ronchese F (2008) Activation and route of administration both determine the ability of bone marrow-derived dendritic cells to accumulate in secondary lymphoid organs and prime CD8(+) T cells against tumors. Cancer Immunol Immunother, 57:63-71
Stoitzner P, Green LK, Jung JY, Price KM, Atarea H, Kivell B, Ronchese F (2008) Inefficient presentation of tumor-derived antigen by tumor-infiltrating dendritic cells. Cancer Immunol Immunother, Mar 1; [Epub ahead of print]
Stoitzner P, Green LK, Jung JY, Price KM, Tripp CH, Malissen B, Kissenpfennig A, Hermans IF, Ronchese F (2008) Tumor immunotherapy by epicutaneous immunization requires Langerhans cells. J Immunol, 180:1991-8
Huck S (2007) Report from the ANZSLAS Conference. NAEAC News, Issue 25: p8
Matthews KE, Karabeg A, Roberts JM, Saeland S, Dekan G, Epstein MM, Ronchese F (2007) Long-term deposition of inhaled antigen in lung resident CD11b-CD11c+ Cells. Am J Respir Cell Mol Biol, 36:435-41
Matthews KE, Qin JS, Yang J, Hermans IF, Palmowski MJ, Cerundolo V, Ronchese F (2007) Increasing the survival of dendritic cells in vivo does not replace the requirement for CD4+ T cell help during primary CD8+ T cell responses. J Immunol, 179:5738-47
Pedersen AE, Ronchese F (2007) CTLA-4 blockade during dendritic cell based booster vaccination influences dendritic cell survival and CTL expansion. J Immune Based Ther Vaccines 5:9
Watt V, Ronchese F, Ritchie DS (2007) Resting B lymphocytes suppress tumour immunity via an MHC class-II dependent mechanism. J Immunother, 30:323-32
Matthews KE, Hermans IF, Roberts JM, Ching LM and Ronchese F (2006) DMXAA treatment of a non-immunogenic tumour does not synergise with active or passive CD8+ T cell immunotherapy. Immunol Cell Biol, 84:383-9
Ohta A, Gorelik E, Prasad S, Ronchese F, Lukashev D, Wong M, Huang X, Caldwell S, Liu K, Smith P, Chen JF, Jackson E, Apasov S, Abrams S, Sitkovsky M (2006) A2A adenosine receptor protects tumors from antitumor T cells. Proc Natl Acad Sci USA, 103:1132-37
Ritchie D, Hermans I, Yang J, Walton J, Matthews K, Carter J, Findlay M, Dady P, Rawson P, Ronchese F (2006) Autologous dendritic cells pulsed with eluted peptide as immunotherapy for advanced B-cell malignancies. Leuk Lymphoma. 47:675-82
Stoitzner P, Tripp CH, Eberhart A, Price KM, Jung JY, Bursch L, Ronchese F, Romani N (2006) Langerhans cells cross-present antigen derived from skin. Proc Natl Acad Sci USA. 103:7783-8
Yang J, Huck SP, McHugh RS, Hermans IF and Ronchese F (2006) Perforin-dependent elimination of dendritic cells regulates the expansion of antigen-specific CD8+ T cells in vivo. Proc Natl Acad Sci USA, 103:147-52
Harris NL, Holloway J, Fitzharris P, McDonald M, Camberis M, Fazekas de St Groth B, Ronchese F, Le Gros G (2005) Tissue localization and frequency of antigen-specific effector CD4 T cells determines the development of allergic airway inflammation. Immunol Cell Biol. 83:490-7
Kemp R, Bäckström T, Ronchese F (2005) The phenotype of Type 1 and Type 2 CD8+ T cells activated in vitro is affected by culture conditions and correlates with effector activity. Immunology, 115(3):315-24
Prasad S, Farrand K, Matthews S, Chang J, McHugh R, Ronchese F (2005) Dendritic cells loaded with stressed tumor cells elicit long lasting protective tumor immunity in mice depleted of CD4+CD25+ regulatory T cells. J Immunol, 174:90-98
van Panhuys N, Perret R, Prout M, Ronchese F, Le Gros G (2005) Effector Lymphoid Tissue and its critical role for protective immunity. Trends in Immunol. 26(5):242-7
Facchinetti A, Gallo P, Perini P, Mezzalira S, Ronchese F, Biasi G (2004) The MBP-reactive repertoire is shaped by recognition of minor histocompatibility antigens. J. Neuroimmunol, 148:154-61
Hermans I, Silk J, Yang J, Gileadi U, Palmowski M, McCarthy C, Ronchese F, Cerundolo V (2004) The VITAL assay: A versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo. J Immunol Methods, 285:25-40
Ritchie DS, Yang J, Hermans IF, Ronchese F (2004) B-Lymphocytes activated by CD40 ligand induce an antigen-specific anti-tumor immune response by direct and indirect activation of CD8+ T-cells. Scand J Immunol, 60:543-51
Roberts JM, Yang J, Ronchese F (2004) IL-4 deficiency does not impair the ability of dendritic cells to initiate CD4+ and CD8+ T cell responses in vivo. Int. Immunol. 16:1451-58
Lumsden, JM, Prasad SJ, Peach RJ, Ronchese F (2003) The effects of B7-dependent costimulation on T cell division and survival in vivo and in vitro are dependent on Ag concentration. Eur J Immunol. 33:2074-2082
Harris N, Watt V, Ronchese, F, Le Gros, G. 2002. Differential T cell function and fate in lymph node and non-lymphoid tissues. J. Exp. Med., 195:317-26.
Ronchese F (2002) Interview about killing of dendritic cells. Modern Aspects of Immunobiology, 2:100
Ronchese F, Prasad S, Ritchie D (2002) Tumour antigens on tap. The Lancet, 360:268
Chtanova T, Kemp R, Sutherland A, Ronchese F, Mackay C (2001) Gene microarrays reveal extensive differential gene expression in both CD4+ and CD8+ type 1 and type 2 T cells. J Immunol, 167:3057-63
Kemp RA, Ronchese F (2001) Tumor-specific Tc1 but not Tc2 cells deliver protective anti-tumor immunity. J Immunol, 167:6497-6502
Harris N, Prout M, Peach R, Fazekas de St Groth B, Ronchese F (2001) CD80 costimulation is required for Th2 cell cytokine production but not for antigen-specific accumulation and migration into the lung. J Immunol, 166:4908-14
Ronchese F, Hermans I (2001) Killing of dendritic cells: a life cut short, or a purposeful death? J Exp Med, 194: F23-6
Hermans I, Ritchie D, Roberts J, Yang J, Ronchese F (2000) CD8+ T cell-dependent elimination of dendritic cells in vivo limits the induction of anti-tumor immunity. J Immunol, 164:3095-101
Lumsden J, Roberts J, Harris N, Peach R, Ronchese F (2000) Differential requirement for CD80 and CD80/CD86 dependent costimulation in the lung immune response to an influenza virus infection. J Immunol, 164:79-85
Rawson P, Hermans I, Huck S, Roberts J, Pircher H, Ronchese, F (2000) Immunotherapy with dendritic cells and tumor MHC Class I-derived peptides requires high density of antigen on tumor cells. Cancer Res, 60:4493-98
Ritchie D, Hermans I, Lumsden J, Scanga C, Roberts J, Yang J, Kemp R, Ronchese F, (2000) Dendritic cell elimination as an assay of cytotoxic T lymphocyte activity in vivo. J Immunol Meth, 246:109-17
Harris N, Peach R, Ronchese F (1999) CTLA4-Ig inhibits optimal T helper 2 cell development but not protective immunity or memory response to Nippostrongylus brasiliensis. Eur J Immunol, 29, 311-316
Harris N, Ronchese F (1999) The role of B7 co-stimulation in T cell immunity. Immunol Cell Biol, 77: 304-311
Hermans I, Ritchie D, Daish A, Yang J, Kehry M, Ronchese F (1999) Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation. J Immunol, 163:77-81
McCoy K, Hermans I, Fraser H, Le Gros G, Ronchese F (1999) Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) can regulate dendritic cell-induced activation and cytotoxicity of CD8+ T cells independently of CD4+ T cell help. J Exp Med, 189:1157-62
Hermans I, Daish A, Yang J, Ritchie D, Ronchese F (1998) Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors. Cancer Res, 58:3909-17
Hermans I, Moroni-Rawson P, Ronchese F, Ritchie D (1998) The emerging role of the dendritic cell in novel cancer therapies. New Zeal Med J 111:111-113
Le Gros G, Erb K, Harris N, Holloway J, McCoy K, Ronchese, F (1998) Immunoregulatory networks in asthma. Clinical & Exp Allergy vol 28, suppl 5, 92-96
Harris N, Campbell C, Le Gros G, Ronchese F (1997) Blockade of CD28/B7 co-stimulation by mCTLA4-H1 inhibits antigen-induced lung eosinophilia but not Th2 cell development or recruitment in the lung. Eur J Immunol, 27:155-161
Harris N, Peach R, Naemura J, Linsley P, Le Gros G, Ronchese F (1997) CD80 co-stimulation is essential for the induction of airway eosinophilia. J Exp Med, 185:177-82
Hermans I, Daish A, Moroni-Rawson P, Ronchese F (1997) Tumor-peptide pulsed dendritic cells isolated from spleen or cultured in vitro from bone marrow precursors can provide protection against tumor challenge. Cancer Immunol Immunother, 44:341-47
Ronchese, F (1997) New strategies for tumour immunotherapy. NZ Science Review, 54:53-57
Garrigan K, Moroni-Rawson P, McMurray C, Hermans I, Abernethy N, Watson J, Ronchese F (1996) Functional comparison of spleen dendritic cells and dendritic cells cultured in vitro from bone marrow precursors. Blood, 88:3508-12.
